SEC Tracker
Get the app

Q32 Bio QTTB

Q32 Bio FY 2025: revenue $53.7M; diluted EPS $2.42

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Q32 Bio reported for the year ended Dec 31, 2025, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$53.7MAgainst $0 in FY 202410-K income statement, on EDGAR
  2. Net income$29.8MAgainst −$47.7M in FY 202410-K income statement, on EDGAR
  3. Diluted EPS$2.42Against −$6.58 in FY 202410-K income statement, on EDGAR
  4. Cash and cash equivalents$48.3M−38% from $78.0M in FY 202410-K balance sheet, on EDGAR
  5. Cash from operations−$33.5MAgainst −$67.7M in FY 202410-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Q32 Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Kiora Pharmaceuticals KPRX public float $10M, Jun 30, 2025
  2. Scienture Holdings SCNX public float $10M, Jun 30, 2025
  3. Traws Pharma ONTX public float $10M, Jun 30, 2025
  4. Alaunos Therapeutics TCRT public float $10M, Jun 30, 2025
  5. Cocrystal Pharma COCP public float $12M, Jun 30, 2025